|
Re: Here's to New 52 week highs
|
3
|
Resverlogix Corp.
|
Sep 05, 2018 01:41PM
|
|
Re: Short Interest in RVXCF at new recent high
|
7
|
Resverlogix Corp.
|
Sep 05, 2018 01:24PM
|
|
Re: Melanotransferrin receptor vs. Transferrin Recepor
|
5
|
BIOASIS TECHNOLOGIES INC
|
Sep 04, 2018 11:50PM
|
|
Re: (one) case study
|
3
|
Zenith Epigenetics
|
Sep 04, 2018 07:54PM
|
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Sep 04, 2018 03:44PM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
3
|
Resverlogix Corp.
|
Sep 04, 2018 01:01PM
|
|
DESIGN AND CHARACTERIZATION OF NOVEL COVALENT BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITORS TARGETING A METHIONINE
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 10:23AM
|
|
Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 09:46AM
|
|
Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
3
|
Zenith Epigenetics
|
Sep 04, 2018 09:05AM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
7
|
Resverlogix Corp.
|
Sep 04, 2018 08:58AM
|
|
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
5
|
Resverlogix Corp.
|
Sep 04, 2018 08:54AM
|
|
Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
4
|
Zenith Epigenetics
|
Sep 04, 2018 08:52AM
|
|
New Apabetalone Clinical Trial for Pulmonary Arterial Hypertension
|
9
|
Resverlogix Corp.
|
Sep 03, 2018 11:34PM
|
|
Re: Vaccinex
|
4
|
BIOASIS TECHNOLOGIES INC
|
Sep 03, 2018 10:59AM
|
|
Re: Vaccinex
|
2
|
BIOASIS TECHNOLOGIES INC
|
Sep 03, 2018 09:13AM
|
|
Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:42PM
|
|
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:27PM
|
|
Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
8
|
Zenith Epigenetics
|
Sep 01, 2018 10:59PM
|
|
Re: Denali Therapeutics Inc. Market Cap. $1.66 Billion today!!!
|
|
BIOASIS TECHNOLOGIES INC
|
Sep 01, 2018 09:43PM
|
|
Re: Perspective on # MACE events and timeline to top-line
|
7
|
Resverlogix Corp.
|
Sep 01, 2018 01:07PM
|
